Subcutaneous mosunetuzumab with step-up dosing plus six cycles of polatuzumab vedotin enabled fully outpatient delivery without mandatory hospitalization, aligning with access and cost-reduction goals ...

A classic combination done right showing how simple ingredients can create something unforgettable #Bagel #NYCFood #Foodie Trump says US caught Chinese 'gift' for Iran, testing red line Popular weight ...

SINGAPORE, April 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA® (lurbinectedin), in combination with atezolizumab ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. The longtime Tiffany & Co.

Combo Devils, a recently kickstarted platform fighter from developer Punkzilla, has one of the best elevator pitches of any fighting game I’ve played in a hot minute: What if we took the core of Smash ...

Randomization enrolled 1841 systemic-therapy–naïve patients within 12 weeks post-surgery to 1 year pembrolizumab plus daily belzutifan or placebo. Disease-free survival improved despite unreached ...

Both trials are ongoing and will report on overall survival at a subsequent analysis. Findings showed the trial met its primary endpoint demonstrating a statistically significant and clinically ...

Private equity firm Cinven is considering a sale of German software company think-cell, which could be valued at as much as €3 billion ($3.5 billion) in a deal, according to people familiar with the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...

The FDA approved lurbinectedin (Zepzelca) plus either atezolizumab (Tecentriq) or atezolizumab and hyaluronidase (Tecentriq Hybreza) as first-line maintenance therapy for extensive-stage small cell ...

Lurbinectedin, combined with atezolizumab or atezolizumab and hyaluronidase, is FDA-approved for ES-SCLC patients without disease progression post-induction therapy. Lurbinectedin is administered ...